Business
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
Five abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis Data
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\nFive abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis\n\nData presentation on pre-clinical asset AUR200 reinforces Aurinia’s commitment to autoimmune disease\n\n VICTORIA, British Columbia--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from multiple studies of LUPKYNIS® (voclosporin), used to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), will be presented at American College of Rheumatology (ACR) Convergence 2022. ACR Convergence 2022 will take place November 10-14 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.\n\nThe abstracts for ACR Convergence 2022 are listed below and available online at: https://acrabstracts.org/meetings/acr-convergence-2022/.\n\nACR Convergence 2022 Oral and Poster Presentations:\n\nTitle: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study\nPresenting author: Amit Saxena, M.D., Assistant Professor, Department of Medicine NYU Grossman School of Medicine\nDate: Saturday, November 12, 2022\nTime: 1:00 p.m - 3:00 p.m ET\nSession: SLE-Treatment Poster I, Abstract 0355\n\nTitle: Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials\nPresenting author: Anca Askanase, M.D., M.P.H., Professor of Medicine, Columbia University Irving Medical Center, Department of Rheumatology\nDate: Saturday, November 12, 2022\nTime: 1:00 p.m - 3:00 p.m ET\nSession: SLE-Treatment Poster I, Abstract 0356\n\nTitle: Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations\nPresenting author: Hans-Joachim Anders, M.D., Professor of Nephrology and Head of Renal Division, University of Munich (LMU)\nDate: Saturday, November 12, 2022\nTime: 1:00 p.m - 3:00 p.m ET\nSession: SLE-Treatment Poster I, Abstract 0357\n\nTitle: Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis\nPresenting author: Ellen M. Ginzler, M.D., M.P...